Literature DB >> 24290434

Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype.

Izabel C J Bandeira1, Lillianne B S Rocha2, Maritza C Barbosa3, Darcielle B D Elias2, José A N Querioz4, Max Vitor Carioca Freitas4, Romélia P Gonçalves4.   

Abstract

The chronic inflammatory state in sickle cell anemia (SCA) is associated with several factors such as the following: endothelial damage; increased production of reactive oxygen species; hemolysis; increased expression of adhesion molecules by leukocytes, erythrocytes, and platelets; and increased production of proinflammatory cytokines. Genetic characteristics affecting the clinical severity of SCA include variations in the hemoglobin F (HbF) level, coexistence of alpha-thalassemia, and the haplotype associated with the HbS gene. The different haplotypes of SCA are Bantu, Benin, Senegal, Cameroon, and Arab-Indian. These haplotypes are associated with ethnic groups and also based on the geographical origin. Studies have shown that the Bantu haplotype is associated with higher incidence of clinical complications than the other haplotypes and is therefore considered to have the worst prognosis. This study aimed to evaluate the profile of the proinflammatory cytokines interleukin-6, tumor necrosis factor-α, and interleukin-17 in patients with SCA and also to assess the haplotypes associated with beta globin cluster S (HBB(*)S). We analyzed a total of 62 patients who had SCA and had been treated with hydroxyurea; they had received a dose ranging between 15 and 25 (20.0±0.6)mg/kg/day for 6-60 (18±3.4)months; their data were compared with those for 30 normal individuals. The presence of HbS was detected and the haplotypes of the beta S gene cluster were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Our study demonstrated that SCA patients have increased inflammatory profile when compared to the healthy individuals. Further, analysis of the association between the haplotypes and inflammatory profile showed that the levels of IL-6 and TNF-α were greater in subjects with the Bantu/Bantu haplotype than in subjects with the Benin/Benin haplotype. The Bantu/Benin haplotype individuals had lower levels of cytokines than those with the Bantu/Bantu haplotype and greater levels than those of subjects with the Benin/Benin haplotype. For IL-17, a slight trend toward decreased levels was observed in the subjects with the Benin/Benin haplotype, when compared to those with the Bantu/Bantu and Bantu/Benin haplotypes; however, this difference was not statistically significant. Our results show that genetic polymorphisms in sickle cell anemia are associated with the inflammatory profile.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytokines; HBB(*)S gene haplotype; Inflammation; Sickle cell anemia

Mesh:

Substances:

Year:  2013        PMID: 24290434     DOI: 10.1016/j.cyto.2013.10.009

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  19 in total

1.  A locus on chromosome 5 shows African ancestry-limited association with alloimmunization in sickle cell disease.

Authors:  Lesedi M Williams; Zhihua Qi; Ken Batai; Stanley Hooker; Nancy J Hall; Roberto F Machado; Alice Chen; Sally Campbell-Lee; Yongtao Guan; Rick Kittles; Neil A Hanchard
Journal:  Blood Adv       Date:  2018-12-26

2.  Inheritance of the Bantu/Benin haplotype causes less severe hemolytic and oxidative stress in sickle cell anemia patients treated with hydroxycarbamide.

Authors:  Jéssika V Okumura; Danilo G H Silva; Lidiane S Torres; Edis Belini-Junior; Willian M Barberino; Renan G Oliveira; Gisele C S Carrocini; Gabriela B Gelaleti; Clarisse L C Lobo; Claudia R Bonini-Domingos
Journal:  J Hum Genet       Date:  2016-03-10       Impact factor: 3.172

3.  IL1A rs1800587 associates with chronic noncrisis pain in sickle cell disease.

Authors:  Xiaoyu Hu; Ellie H Jhun; Yingwei Yao; Ying He; Robert E Molokie; Diana J Wilkie; Zaijie J Wang
Journal:  Pharmacogenomics       Date:  2016-11-24       Impact factor: 2.533

4.  Influence of β-Globin Haplotypes on Oxidative Stress, Antioxidant Capacity and Inflammation in Sickle Cell Patients of Chhattisgarh.

Authors:  Sanjana Bhagat; Amar Singh Thakur
Journal:  Indian J Clin Biochem       Date:  2018-01-06

Review 5.  Emerging point-of-care technologies for sickle cell disease screening and monitoring.

Authors:  Yunus Alapan; Arwa Fraiwan; Erdem Kucukal; M Noman Hasan; Ryan Ung; Myeongseop Kim; Isaac Odame; Jane A Little; Umut A Gurkan
Journal:  Expert Rev Med Devices       Date:  2016-11-22       Impact factor: 3.166

6.  High levels of proinflammatory cytokines IL-6 and IL-8 are associated with a poor clinical outcome in sickle cell anemia.

Authors:  Igor F Domingos; Diego A Pereira-Martins; Marcondes J V C Sobreira; Romulo T D Oliveira; Adekunle E Alagbe; Carolina Lanaro; Dulcineia M Albuquerque; Maria H S L Blotta; Aderson S Araujo; Fernando F Costa; Antonio R Lucena-Araujo; Maria F Sonati; Marcos A C Bezerra; Magnun N N Santos
Journal:  Ann Hematol       Date:  2020-03-05       Impact factor: 3.673

7.  Quantitative sensory testing and pain-evoked cytokine reactivity: comparison of patients with sickle cell disease to healthy matched controls.

Authors:  Claudia M Campbell; C Patrick Carroll; Kasey Kiley; Dingfen Han; Carlton Haywood; Sophie Lanzkron; Lauren Swedberg; Robert R Edwards; Gayle G Page; Jennifer A Haythornthwaite
Journal:  Pain       Date:  2016-04       Impact factor: 7.926

8.  Comment on "Influence of βS-globin haplotypes and hydroxyurea on tumor necrosis factor-alpha levels in sickle cell anemia".

Authors:  Lidiane de Souza Torres
Journal:  Rev Bras Hematol Hemoter       Date:  2014-03

9.  C-reactive Protein and Disease Outcome in Nigerian Sickle Cell Disease Patients.

Authors:  Ce Okocha; Po Manafa; Jo Ozomba; To Ulasi; Go Chukwuma; Jc Aneke
Journal:  Ann Med Health Sci Res       Date:  2014-09

10.  Interethnic diversity of the CD209 (rs4804803) gene promoter polymorphism in African but not American sickle cell disease.

Authors:  Jenelle A Noble; Kimberley C Duru; Aldiouma Guindo; Li Yi; Ikhide G Imumorin; Dapa A Diallo; Bolaji N Thomas
Journal:  PeerJ       Date:  2015-02-24       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.